A Vaccine for the Pandemic of Aging? Conceptual and Ethical Issues

Wareham, Christopher; García-Barranquero, Pablo

doi:10.1007/978-981-19-7443-4_15

Cited by 1 publication

(2 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Premature ageing is a common phenomenon among low-income people, 58 and noncommunicable diseases (often related to ageing) are a great cause of death in these countries. 59 Age-related conditions such as ischaemic heart diseases and strokes are the third and fourth causes of death according to the World Health Organization. 60 In addition, given the breadth of the medical enterprise, the fight against specific priorities of low-income countries is not incompatible with improvements in lifespan and healthspan using antiageing pharmaceuticals.…”

Section: Argument Of Fair Distribution Of the Medicationmentioning

confidence: 99%

“…61 This type of argument has been rejected because of its moral crudity. 62 No one with a sufficient level of empathy would agree to ban COVID-19 vaccines because they, by especially extending the lives of the older population, put more pressure on pensions and the wider economy. The same should be applied to antiageing treatments.…”

Section: Argument Of Economic Unsustainabilitymentioning

confidence: 99%

See 1 more Smart Citation

Should the European Medicines Agency consider ageing a disease?

Marín Penella

2024

Bioethics

View full text Add to dashboard Cite

The classification of ageing as a disease is fundamental to developing new pharmacological strategies that can target said phenomenon. The European Medicines Agency does not do this and maintains a questionable perspective based on the traditional naturalistic argument and the value‐free ideal. An alternative is proposed which, inspired by consequentialism, is committed to considering ageing as a disease in European regulatory contexts as long as the ethical consequences are desirable. Within a realistic framework, I show that making this decision would have moderate positive effects such as increased knowledge about antiageing pharmacology or potential greater chances of completing vital projects. Furthermore, we will see that the main arguments used by critics to show that the negative effects outweigh the positive ones are not sound. Therefore, I conclude that it would be beneficial for the European Medicines Agency to change its position on ageing.

show abstract

Section: Argument Of Fair Distribution Of the Medicationmentioning

confidence: 99%

Section: Argument Of Economic Unsustainabilitymentioning

confidence: 99%